Clinical Trial Update: Evaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the safety and efficacy of once-monthly ranibizumab injections for wet age-related macular degeneration in Chinese patients has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Age Related Macular Degeneration | Phase 3 | Status: COMPLETED